NotíciasBenzingaReported Saturday, Johnson & Johnson Says Patient Insights From Phase 2 DAHLIAS Study Helped Inform Phase 3 Nipocalimab Design, With 73.5% Of Interviewed Patients Satisfied Or Very Satisfied With Treatment In Sjögren’s Disease Reported Saturday, Johnson & Johnson Says Patient Insights From Phase 2 DAHLIAS Study Helped Inform Phase 3 Nipocalimab Design, With 73.5% Of Interviewed Patients Satisfied Or Very Satisfied With Treatment In Sjögren’s Disease Benzinga 2026.11.09 08:38 (GMT+0) Abrir em Benzinga Outras notícias Petrobras (PETR4), PicPay (PICS), Ambipar (AMBP3) e outros destaques desta terça-feira (17) UBS inicia cobertura da Meta Platforms com recomendação de compra UBS inicia cobertura da Alphabet Inc Class C com recomendação neutra UBS inicia cobertura da Amazon.com com recomendação de compra por perspectiva de IA Comissão Europeia aprova dosagem flexível do Libtayo da Regeneron KAYAK adiciona recursos de IA com preços em tempo real para buscas flexíveis